ReviewCancers2024
FAPi-Based Agents in Thyroid Cancer: A New Step towards Diagnosis and Therapy? A Systematic Review of the Literature.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Revolutionizing cancer diagnosis and dose biodistribution: a meta-analysis of [68ga] FAPI- 46 vs. [18f] FDG imaging.Systematic reviews · 2025Pooled it
- Clinical performance of [European journal of nuclear medicine and molecular imaging · 2026Article
- FROM DISCOVERY SCIENCE TO THE CLINIC - HERITABLE ENDOCRINE CANCERS AND RELATED DISORDERS: Functional imaging in hereditary endocrine neoplasms: evolving modalities and clinical implications.Endocrine-related cancer · 2026Review
- Multimodal strategies for diagnosing and treating thyroid cancer: Advances in basic and clinical research.Translational oncology · 2026Review
- Long-term outcomes in medullary thyroid cancer patients treated with [EJNMMI research · 2026Article
- Observation on Discordant Treatment Response on [World journal of nuclear medicine · 2026Article
- Fibroblast Activation Protein Inhibitor (FAPI) PET: A Scoping Review of Emerging Oncologic and Fibroinflammatory Applications.Diagnostics (Basel, Switzerland) · 2026Review
- Multiple Unusual Distant Metastasis in TENIS: Comparative Evaluation of [World journal of nuclear medicine · 2026Article
- Multidisciplinary team diagnosis and treatment of well-differentiated thyroid carcinoma: current landscape and future prospects.The oncologist · 2026Review
- Roles and subtypes of cancer-associated fibroblasts (CAFs) in thyroid cancer.American journal of cancer research · 2026Review
- Meta-Analysis on the Prevalence and Significance of Incidental Findings in the Thyroid Gland Using Other PET Radiopharmaceuticals Beyond [Pharmaceuticals (Basel, Switzerland) · 2025Review
- Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Review
- Emerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [Molecular diagnosis & therapy · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 17 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Background: Thyroid cancer (TC) is often treated with surgery followed by iodine-131. Up to 50% of the instances of TC lose their avidity to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.